Budapest Post

Cum Deo pro Patria et Libertate
Budapest, Europe and world news

Hong Kong looking to procure world’s first Covid-19 pill

Hong Kong looking to procure world’s first Covid-19 pill

Sources tell the Post that Hospital Authority is planning to buy hundreds of courses of the antiviral medication, known as molnupiravir.

Hong Kong is in the process of securing the world’s first Covid-19 pill, which the manufacturers claim can cut hospitalisations and deaths by half.

Sources told the Post that health authorities planned to buy hundreds of courses of the antiviral medication, which made headlines on Friday after pharmaceutical giant MSD and its partner Ridgeback Biotherapeutics released promising results from their trials.

The trials involved 775 adults with mild to moderate Covid-19 who were randomly picked from more than 20 countries and deemed to be highly prone to severe illness due to health problems such as obesity, diabetes or heart disease.

Half of the trial participants were given a five-day course of the experimental drug, known as molnupiravir, in the form of small, brown capsules taken twice a day, while the others received a placebo. According to the results, only 28 patients, or 7.3 per cent, of those given the drug were hospitalised, compared with 53, or 14.1 per cent, in the placebo group.

After the trial, no deaths were reported among those who received the drug, while the placebo group had eight. The data, however, has not been peer-reviewed and the drug has not yet been licensed for use.

Three medical sources confirmed to the Post that Hong Kong was looking to procure the medication.

“The Hospital Authority plans to purchase 500 patient courses, but they are also thinking about more,” Professor David Hui Shu-cheong, a government pandemic adviser, said on Saturday.

Professor David Hui.


He revealed that the drug costs about US$700 per course for each patient.

Hui and other authority doctors said they hoped the matter would be discussed at the next meeting of the Centre for Health Protection’s joint scientific committees, which was likely to take place in late October or early November.

Another source familiar with the matter said negotiations between MSD, which trades as Merck in North America, and the authority were continuing and that “no paperwork has been signed” yet.

A third source said the drug could be approved for emergency use to treat severely ill patients although it was not yet licensed by local health authorities.

“It would, however, be difficult to conduct any local study on its effectiveness, as we fortunately have so few patients in the community, and most imported cases have a low viral load,” the health expert said.

Infectious disease expert Professor Ivan Hung Fan-ngai, who has looked at the trial data, said molnupiravir achieved the best results with a daily dosage of 800 milligrams given in the first week of illness, rather than lower amounts of 400 or 200 milligrams.

“It works best when given early and results in fewer hospitalisations and deaths subsequently,” he said.

Merck, which trades as MSD outside North America, released trial data on Friday.


Hung, who co-chairs a government panel on adverse vaccine effects, noted the city’s cocktail therapy for Covid-19 centred on the antiviral interferon, which also achieved its best results when given early.

“In general, early treatment is the key to success for all antivirals,” he said.

A Hospital Authority source said it had been monitoring the drug’s development.

“It has been on our radar all along, but we can’t say how the company will distribute the drug globally,” the source said, noting that US authorities had yet to authorise the pill for emergency use.

An authority spokesman said its experts had been closely monitoring the latest developments in the pandemic and clinical research. It would buy and stock medications for Covid-19 when necessary, after taking reference from the latest data from worldwide drug regulatory agencies and manufacturers.

The authority would ensure patients were prescribed new medications that were proven safe and effective, the spokesman said.

The Department of Health said it had not received any application for the registration of molnupiravir. Under the Pharmacy and Poisons Ordinance, doctors can import drugs that are not yet registered in the city for treating specific patients or conducting clinical trials.

MSD said it would apply for approval for emergency use for the drug in the United States within the next two weeks and make applications in several other countries as well.

The Post has contacted the drugmaker for comment.

AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
Newsletter

Related Articles

0:00
0:00
Close
16 Billion Login Credentials Leaked in Unprecedented Cybersecurity Breach
Senate hearing on who was 'really running' Biden White House kicks off
Hungary Ranked Among the World’s Safest Travel Destinations for 2025
G7 Leaders Fail to Reach Consensus on Key Global Issues
FBI and Senate Investigate Allegations of Chinese Plot to Influence the 2020 Election in Biden’s Favor Using Fake U.S. Driver’s Licenses
Trump Demands Iran's Unconditional Surrender Amid Escalating Conflict
Shock Within Iran’s Leadership: Khamenei’s Failed Plan to Launch 1,000 Missiles Against Israel
Wreck of $17 Billion San José Galleon Identified Off Colombia After 300 Years
Man Convicted of Fraud After Booking Over 120 Free Flights Posing as Flight Attendant
Iran Launches Extensive Missile Attack on Israel Following Israeli Strikes on Nuclear Sites
Beata Thunberg Rebrands as Beata Ernman Amidst Sister's Activism Controversy
Hungarian Parliament Approves Citizenship Suspension Law
Prime Minister Orbán Criticizes EU's Ukraine Accession Plans
Hungarian Delicacies Introduced to Japanese Market
Hungary's Industrial Output Rises Amid Battery Sector Slump
President Sulyok Celebrates 15 Years of Hungarian Unity Efforts
Hungary's Szeleczki Shines at World Judo Championships
Visegrád Construction Trends Diverge as Hungary Lags
Hungary Hosts National Quantum Technology Workshop
Hungarian Animation Featured at Annecy Festival
Israel Issues Ultimatum to Iran Over Potential Retaliation and Nuclear Facilities
UK and EU Reach New Economic Agreement
Coinbase CEO Warns Bitcoin Could Supplant US Dollar Amid Mounting National Debt
Trump to Iran: Make a Deal — Sign or Die
Operation "Like a Lion": Israel Strikes Iran in Unprecedented Offensive
Israel Launches 'Operation Rising Lion' Targeting Iranian Nuclear and Military Sites
UK and EU Reach Agreement on Gibraltar's Schengen Integration
Israeli Finance Minister Imposes Banking Penalties on Palestinians
U.S. Inflation Rises to 2.4% in May Amid Trade Tensions
Trump's Policies Prompt Decline in Chinese Student Enrollment in U.S.
Global Oceans Near Record Temperatures as CO₂ Levels Climb
Trump Announces U.S.-China Trade Deal Covering Rare Earths
Smuggled U.S. Fuel Funds Mexican Cartels Amid Crackdown
Austrian School Shooting Leaves Nine Dead in Graz
Bezos's Lavish Venice Wedding Sparks Local Protests
Europe Prepares for Historic Lunar Rover Landing
Italian Parents Seek Therapy Amid Lengthy School Holidays
British Fishing Vessel Seized by France Fined €30,000
Dutch Government Collapses Amid Migration Policy Dispute
UK Commits to 3.5% GDP Defence Spending Under NATO Pressure
Germany Moves to Expedite Migrant Deportations
US Urges UK to Raise Defence Spending to 5% of GDP
Israeli Forces Intercept Gaza-Bound Aid Vessel Carrying Greta Thunberg
IMF Warns of Severe Global Trade War Impacts on Emerging Markets
Low Turnout Jeopardizes Italy's Citizenship Reform Referendum
Transatlantic Interest Rate Divergence Widens as Trump Pressures Powell
EU Lawmaker Calls for Broader Exemptions in Supply Chain Legislation
France's Defense Spending Plans Threatened by High National Debt
European Small-Cap Stocks Outperform U.S. Rivals Amid Growth Revival
Switzerland Proposes $26 Billion Capital Increase for UBS
×